Posted by Michael Wonder on 14 Jul 2017
Janssen announces U.S. FDA approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis
13 July 2017 - Tremfya is the first and only biologic approved that selectively blocks interleukin 23.
Janssen Biotech announced today that the U.S. FDA has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only interleukin 23, a cytokine that plays a key role in plaque psoriasis.
Approval comes after an expedited regulatory review following application of an FDA priority review voucher.
